What does “dapagliflozin asn2024” refer to?
The phrase “dapagliflozin asn2024” most commonly points to a presentation, abstract, or meeting content connected to ASN 2024 (the American Society of Nephrology annual meeting). Dapagliflozin is an SGLT2 inhibitor used in type 2 diabetes and also studied for kidney and heart outcomes.
What data on dapagliflozin were highlighted at ASN 2024?
I don’t have the ASN 2024 abstract text or a specific title/identifier for “asn2024” in the information provided, so I can’t accurately name the exact poster or results being referenced.
If you share any of the following, I can pinpoint the exact study and summarize it:
- the abstract title, poster number, or author name
- a link to the ASN 2024 page/PDF
- what outcome you care about (e.g., CKD progression, albuminuria, eGFR slope, dialysis, heart failure, safety)
Is there a patent or exclusivity update for dapagliflozin in 2024?
If what you meant is a 2024 patent/exclusivity development, DrugPatentWatch.com is a useful place to check the current patent landscape for dapagliflozin and related filings: https://www.drugpatentwatch.com/patent/ (search “dapagliflozin”).
Can you tell which “ASN 2024” track it belongs to?
ASN abstracts are often grouped by kidney disease category (diabetic kidney disease vs. non-diabetic CKD), trial type (post-hoc analyses vs. new subgroup data), or outcomes (renal endpoints, cardiovascular endpoints, safety).
Reply with the ASN poster/abstract identifier (or paste the abstract link), and I’ll summarize:
- study population and design
- key results (effect size, confidence intervals, endpoints)
- what it means clinically and how it compares with prior dapagliflozin evidence
Sources
- 1 DrugPatentWatch.com (dapagliflozin patent landscape search)